Home Newsfeeds SEC Says China Health Industries Holdings, Hollysys Automation Technologies Identified Under HFCAA

SEC Says China Health Industries Holdings, Hollysys Automation Technologies Identified Under HFCAA

-Reuters

byBenzinga Newsdesk

September 28, 2022

1 minute read

-Reuters

Noah Holdings Q2 EPS $0.79 Up From $0.77 YoY, Sales $110.20M Down From $139.30M YoY

By Michael Horton

August 22, 5:02 PM

Noah Holdings (NYSE:NOAH) reported quarterly earnings of $0.79 per share. This is a 2.6 percent increase over earnings of $0.77 per share from the same period last year. The company reported $110.20 million in sales

NOAH

Bitcoin’s Price Rebound Triggers Rally In Crypto-Linked Stocks As Expert Highlights ‘Very Bullish Long Term’ Outlook

By Rounak Jain

January 27, 2:55 AM

In the wake of a more than 4% surge in Bitcoin’s (CRYPTO: BTC) price over the last 24 hours, stocks linked to the cryptocurrency have experienced a notable increase.

ANY

FDA Presses Delay Button For Applied Therapeutics’ First Potential Marketed Drug For Rare Disease

By Vandana Singh

April 1, 12:30 PM

FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.

APLT

Logitech Raises FY24 Revenue Guidance Outlook From $3.8B-$4B To $4B-$4.15B Vs $4.02B Est.

By Benzinga Newsdesk

October 23, 10:28 PM

Updated Full Year OutlookLogitech raised its full-year outlook for Fiscal Year 2024: Previous FY 2024 outlookNew FY 2024 outlookSales$3.8 - $4.0 billion$4.0 - $4.15 billionSales decline (in US dollars, year over

LOGI

SEC Says China Health Industries Holdings, Hollysys Automation Technologies Identified Under HFCAA

Related Posts

Noah Holdings Q2 EPS $0.79 Up From $0.77 YoY, Sales $110.20M Down From $139.30M YoY

Bitcoin’s Price Rebound Triggers Rally In Crypto-Linked Stocks As Expert Highlights ‘Very Bullish Long Term’ Outlook

FDA Presses Delay Button For Applied Therapeutics’ First Potential Marketed Drug For Rare Disease

Logitech Raises FY24 Revenue Guidance Outlook From $3.8B-$4B To $4B-$4.15B Vs $4.02B Est.